RxDoctor Payments Data

Amy Murphy, MD

Family Medicine · Carrollton, TXNPI 1780627836

Payments from drug & device makers

$12,147in general payments, 2019–2025

Across 707 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$994
  • Pfizer$786
  • AstraZeneca$727
  • Lilly USA, LLC$524
  • Johnson & Johnson$513
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$12,04799%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,147 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$47,016
Medicare patients
139
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$64,024
JardianceEmpagliflozin66$58,272
FarxigaDapagliflozin Propanediol58$50,559
JanuviaSitagliptin Phosphate13$21,685
MyrbetriqMirabegron22$15,689
TrulicityDulaglutide14$15,025
Pravastatin Sodium77$1,326
Levothyroxine Sodium188$1,306
Atorvastatin Calcium181$1,170
SynthroidLevothyroxine Sodium22$1,077
Ibandronate Sodium51$1,033
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide20$922
Escitalopram Oxalate108$839
Metoprolol Succinate64$793
Rosuvastatin Calcium94$790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$994$64,02449 claims
Boehringer IngelheimJardiance$341$58,27266 claims
AstraZenecaFarxiga$727$50,55958 claims
MerckJanuvia$428$21,68513 claims
Astellas Pharma US IncMyrbetriq$404$15,68922 claims
Lilly USA, LLCTrulicity$524$15,02514 claims
AbbVieSynthroid$1,649$1,07722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Carrollton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →